Tolerance of centrifuge-simulated suborbital spaceflight in subjects with implanted insulin pumps

Dana R. Levin, Rebecca Blue, Tarah L. Castleberry, James M. Vanderploeg

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

INTRODUCTION: With commercial spaceflight comes the possibility of spaceflight participants (SFPs) with significant medical conditions. Those with previously untested medical conditions, such as diabetes mellitus (DM) and the use of indwelling medical devices, represent a unique challenge. It is unclear how SFPs with such devices will react to the stresses of spaceflight. This case report describes two subjects with Type I DM using insulin pumps who underwent simulated dynamic phases of spaceflight via centrifuge G force exposure.

CASE REPORT: Two Type I diabetic subjects with indwelling Humalog insulin pumps, a 23-yr-old man averaging 50 u of Humalog daily and a 27-yr-old man averaging 60 u of Humalog daily, underwent seven centrifuge runs over 48 h. Day 1 consisted of two +Gz runs (peak = +3.5 Gz, run 2) and two +Gx runs (peak = +6.0 Gx, run 4). Day 2 consisted of three runs approximating suborbital spaceflight profiles (combined +Gx and +Gz). Data collected included blood pressure, electrocardiogram, pulse oximetry, neurovestibular evaluation, and questionnaires regarding motion sickness, disorientation, greyout, and other symptoms. Neither subject experienced adverse clinical responses to the centrifuge exposure. Both maintained blood glucose levels between 110-206 mg · dl(-1).

DISCUSSION: Potential risks to SFPs with insulin pump dependent DM include hypo/hyperglycemia, pump damage, neurovestibular dysfunction, skin breakdown, and abnormal stress responses. A search of prior literature did not reveal any previous studies of individuals with DM on insulin pumps exposed to prolonged accelerations. These cases suggest that individuals with conditions dependent on continuous medication delivery might tolerate the accelerations anticipated for commercial spaceflight.

Original languageEnglish (US)
Pages (from-to)407-409
Number of pages3
JournalAerospace medicine and human performance
Volume86
Issue number4
DOIs
StatePublished - Apr 1 2015

Fingerprint

Space Flight
Insulin
Insulin Lispro
Type 1 Diabetes Mellitus
Diabetes Mellitus
Motion Sickness
Equipment and Supplies
Oximetry
Gravitation
Hyperglycemia
Blood Glucose
Electrocardiography
Blood Pressure
Skin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tolerance of centrifuge-simulated suborbital spaceflight in subjects with implanted insulin pumps. / Levin, Dana R.; Blue, Rebecca; Castleberry, Tarah L.; Vanderploeg, James M.

In: Aerospace medicine and human performance, Vol. 86, No. 4, 01.04.2015, p. 407-409.

Research output: Contribution to journalArticle

Levin, Dana R. ; Blue, Rebecca ; Castleberry, Tarah L. ; Vanderploeg, James M. / Tolerance of centrifuge-simulated suborbital spaceflight in subjects with implanted insulin pumps. In: Aerospace medicine and human performance. 2015 ; Vol. 86, No. 4. pp. 407-409.
@article{bb29fe8f50414ee580882c057c2511f3,
title = "Tolerance of centrifuge-simulated suborbital spaceflight in subjects with implanted insulin pumps",
abstract = "INTRODUCTION: With commercial spaceflight comes the possibility of spaceflight participants (SFPs) with significant medical conditions. Those with previously untested medical conditions, such as diabetes mellitus (DM) and the use of indwelling medical devices, represent a unique challenge. It is unclear how SFPs with such devices will react to the stresses of spaceflight. This case report describes two subjects with Type I DM using insulin pumps who underwent simulated dynamic phases of spaceflight via centrifuge G force exposure.CASE REPORT: Two Type I diabetic subjects with indwelling Humalog insulin pumps, a 23-yr-old man averaging 50 u of Humalog daily and a 27-yr-old man averaging 60 u of Humalog daily, underwent seven centrifuge runs over 48 h. Day 1 consisted of two +Gz runs (peak = +3.5 Gz, run 2) and two +Gx runs (peak = +6.0 Gx, run 4). Day 2 consisted of three runs approximating suborbital spaceflight profiles (combined +Gx and +Gz). Data collected included blood pressure, electrocardiogram, pulse oximetry, neurovestibular evaluation, and questionnaires regarding motion sickness, disorientation, greyout, and other symptoms. Neither subject experienced adverse clinical responses to the centrifuge exposure. Both maintained blood glucose levels between 110-206 mg · dl(-1).DISCUSSION: Potential risks to SFPs with insulin pump dependent DM include hypo/hyperglycemia, pump damage, neurovestibular dysfunction, skin breakdown, and abnormal stress responses. A search of prior literature did not reveal any previous studies of individuals with DM on insulin pumps exposed to prolonged accelerations. These cases suggest that individuals with conditions dependent on continuous medication delivery might tolerate the accelerations anticipated for commercial spaceflight.",
author = "Levin, {Dana R.} and Rebecca Blue and Castleberry, {Tarah L.} and Vanderploeg, {James M.}",
year = "2015",
month = "4",
day = "1",
doi = "10.3357/AMHP.4134.2015",
language = "English (US)",
volume = "86",
pages = "407--409",
journal = "Aerospace medicine and human performance",
issn = "2375-6314",
publisher = "Aerospace Medical Association",
number = "4",

}

TY - JOUR

T1 - Tolerance of centrifuge-simulated suborbital spaceflight in subjects with implanted insulin pumps

AU - Levin, Dana R.

AU - Blue, Rebecca

AU - Castleberry, Tarah L.

AU - Vanderploeg, James M.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - INTRODUCTION: With commercial spaceflight comes the possibility of spaceflight participants (SFPs) with significant medical conditions. Those with previously untested medical conditions, such as diabetes mellitus (DM) and the use of indwelling medical devices, represent a unique challenge. It is unclear how SFPs with such devices will react to the stresses of spaceflight. This case report describes two subjects with Type I DM using insulin pumps who underwent simulated dynamic phases of spaceflight via centrifuge G force exposure.CASE REPORT: Two Type I diabetic subjects with indwelling Humalog insulin pumps, a 23-yr-old man averaging 50 u of Humalog daily and a 27-yr-old man averaging 60 u of Humalog daily, underwent seven centrifuge runs over 48 h. Day 1 consisted of two +Gz runs (peak = +3.5 Gz, run 2) and two +Gx runs (peak = +6.0 Gx, run 4). Day 2 consisted of three runs approximating suborbital spaceflight profiles (combined +Gx and +Gz). Data collected included blood pressure, electrocardiogram, pulse oximetry, neurovestibular evaluation, and questionnaires regarding motion sickness, disorientation, greyout, and other symptoms. Neither subject experienced adverse clinical responses to the centrifuge exposure. Both maintained blood glucose levels between 110-206 mg · dl(-1).DISCUSSION: Potential risks to SFPs with insulin pump dependent DM include hypo/hyperglycemia, pump damage, neurovestibular dysfunction, skin breakdown, and abnormal stress responses. A search of prior literature did not reveal any previous studies of individuals with DM on insulin pumps exposed to prolonged accelerations. These cases suggest that individuals with conditions dependent on continuous medication delivery might tolerate the accelerations anticipated for commercial spaceflight.

AB - INTRODUCTION: With commercial spaceflight comes the possibility of spaceflight participants (SFPs) with significant medical conditions. Those with previously untested medical conditions, such as diabetes mellitus (DM) and the use of indwelling medical devices, represent a unique challenge. It is unclear how SFPs with such devices will react to the stresses of spaceflight. This case report describes two subjects with Type I DM using insulin pumps who underwent simulated dynamic phases of spaceflight via centrifuge G force exposure.CASE REPORT: Two Type I diabetic subjects with indwelling Humalog insulin pumps, a 23-yr-old man averaging 50 u of Humalog daily and a 27-yr-old man averaging 60 u of Humalog daily, underwent seven centrifuge runs over 48 h. Day 1 consisted of two +Gz runs (peak = +3.5 Gz, run 2) and two +Gx runs (peak = +6.0 Gx, run 4). Day 2 consisted of three runs approximating suborbital spaceflight profiles (combined +Gx and +Gz). Data collected included blood pressure, electrocardiogram, pulse oximetry, neurovestibular evaluation, and questionnaires regarding motion sickness, disorientation, greyout, and other symptoms. Neither subject experienced adverse clinical responses to the centrifuge exposure. Both maintained blood glucose levels between 110-206 mg · dl(-1).DISCUSSION: Potential risks to SFPs with insulin pump dependent DM include hypo/hyperglycemia, pump damage, neurovestibular dysfunction, skin breakdown, and abnormal stress responses. A search of prior literature did not reveal any previous studies of individuals with DM on insulin pumps exposed to prolonged accelerations. These cases suggest that individuals with conditions dependent on continuous medication delivery might tolerate the accelerations anticipated for commercial spaceflight.

UR - http://www.scopus.com/inward/record.url?scp=84930747616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930747616&partnerID=8YFLogxK

U2 - 10.3357/AMHP.4134.2015

DO - 10.3357/AMHP.4134.2015

M3 - Article

C2 - 25945560

AN - SCOPUS:84930747616

VL - 86

SP - 407

EP - 409

JO - Aerospace medicine and human performance

JF - Aerospace medicine and human performance

SN - 2375-6314

IS - 4

ER -